Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 18, Issue 7, 2006, Pages 663-673

  Reynolds, Nancy R ^a   Neidig, J L ^a   Wu, A W ^b   Gifford, A L ^c,d   Holmes, W C ^c,e  

^a OHIO STATE UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; ARTICLE; BODY FAT DISTRIBUTION; CONTROLLED STUDY; DEFORMITY; DISEASE COURSE; FEMALE; HEALTH BEHAVIOR; HEALTH CARE PERSONNEL; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; LIPODYSTROPHY; MALE; PATIENT ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; SELF CONCEPT; SEXUAL BEHAVIOR; SEXUAL ORIENTATION; SOCIAL PROBLEM; SYMPTOM; TREATMENT REFUSAL; UNITED STATES;

ADIPOSE TISSUE; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY IMAGE; DISEASE PROGRESSION; FEAR; FEMALE; FOCUS GROUPS; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; SELF CONCEPT; STRESS, PSYCHOLOGICAL; UNITED STATES;

EID: 33748684776     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120500287051     Document Type: Article

References (68)

1. Ablon, J. (1981). Stigmatized health conditions. Social Science and Medicine, 15B, 5-9.
2. AIDS Clinical Trials Group, NIH/NIAID, Outcomes Committee. Assessment of body change and distress n.d. Available at Adult Quality of Life Forms Downloading Area, http://www.fstrf.org/qol/aactg/adult-ql.html. Accessed May 31 2006.
3. Ainlay, S.C., Becker, G., & Coleman, L.M. (1986). Stigma reconsidered. In S.C. Ainlay, G. Becker, & L.M. Coleman (Eds.), The dilemma of difference: A multidisciplinary view of stigma (pp. 1-13). New York: Plenum Press.
4. Alonzo, A.A., & Reynolds, N.R. (1995). Stigma, HIV and AIDS: An exploration and elaboration of a stigma trajectory. Social Science and Medicine, 41, 303-315.
5. Ammassari, A., Antinori, A., Cozzi-Lepri, A., Trotta, M.P., Nasti, G., Ridolfo, A.L., et al. (2002). Relationship between HAART adherence and adipose tissue alterations. Journal of Acquired Immune Deficiency Syndrome, 31(Suppl. 3), S140-S144.
6. Barbaro, G. (2003). Highly active antiretroviral therapy and the cardiovascular system: The heart of the matter. Pharmacology, 69, 177-179.
7. Barbaro, G., Di Lorenzo, G., Cirelli, A., Grisorio, B., Lucchini, A., Hazra, C., et al. (2003). An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clinical Therapeutics, 25, 2405-2418.
8. Belloso, W.H., Quiros, R.E., Ivalo, S.A., Perman, M.I., Galich, A.M., Stern, L.D., et al. (2003). Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients. Journal of Acquired Immune Deficiency Syndrome, 32, 104-111.
9. Bernasconi, E., Boubaker, K., Junghans, C., Flepp, M., Furrer, H.J., Haensel, A., et al. (2002). Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV cohort study. Journal Acquired Immune Deficiency Syndrome, 31, 50-55.
10. Blanch, J., Rousaud, A., Martinez, E., De Lazzari, E., Peri, J.M., Milinkovic, A., et al. (2002). Impact of lipodystrophy on the quality of life of HIV-1-infected patients. Journal Acquired Immune Deficiency Syndrome, 31, 404-407.
11. Carr, A. (2003). HIV lipodystrophy: Risk factors, pathogenesis, diagnosis and management. Aids, 17(Suppl. 1), S141-S148.
12. Carr, A., Emery, S., Law, M., Puls, R., Lundgren, J.D., & Powderly, W.G. (2003). An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet, 361, 726-735.
13. Chen, D., Misra, A., & Garg, A. (2002). Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. The Journal of Clinical Endocrinology & Metabolism, 87, 4845-4856.
14. Cofrancesco, J. Jr., Brown, T., & Martins, C.R. (2004). Management options for facial lipoatrophy. AIDS Reader, 14, 639-640, 645-650.
15. Colagreco, J.P. (2004). Cardiovascular considerations in patients treated with HIV protease inhibitors. Journal of the Association of Nurses in AIDS Care, 15, 30-41.
16. Conrad, P. (1986). The social meaning of AIDS. Social Policy, 20, 51-61.
17. Corless, I.B., Nicholas, P.K., Mcgibbon, C.A., & Wilson, C. (2004). Weight change, body image and quality of life in HIV disease: A pilot study. Applied Nursing Research, 17, 292-296.
18. Cotter, B.R., & Torriani, F.J. (2004). Cardiovascular effects of antiretroviral therapy and noninvasive assessments of cardiovascular disease in HIV infection. Journal of Cardiovascular Toxicology, 4, 281-286.
19. Ena, J., Benito, C., Llacer, P., Pasquau, F., & Amador, C. (2004). Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients. Clinical Medicine, 122, 721-726.
20. Engelson, E.S. (2003a). HIV lipodystrophy diagnosis and management. Body composition and metabolic alterations: Diagnosis and management. AIDS Reader, 13, S10-S14.
21. Engelson, E.S. (2003b). Interventions for visceral adiposity associated with human immunodeficiency virus: Application of a method for assessing efficacy. Clinical Infectious Diseases, 37(Suppl. 2), S96-S100.
22. Fife, B.L., & Wright, E.R. (2000). The dimensionality of stigma: A comparison of its impact on the self of persons with HIV/AIDS and cancer. Journal of Health and Social Behavior, 41, 50-67.
23. Gervasoni, C., Ridolfo, A.L., Vaccarezza, M., Fedeli, P., Morelli, P., Rovati, L., et al. (2004). Long-term efficacy of the surgical treatment of buffalo hump in patients continuing antiretroviral therapy. Aids, 18, 574-576.
24. Goffman, E. (1963). Stigma: Notes on the management of a spoiled identity. Englewood Cliffs, New Jersey: Prentice-Hall.
25. Green, M.L. (2002). Evaluation and management of dyslipidemia in patients with HIV infection. Journal of General Internal Medicine, 17, 797-810.
26. Grinspoon, S., & Carr, A. (2005). Cardiovascular risk and bodyfat abnormalities in HIV-infected adults. New England Journal of Medicine, 352, 48-62.
27. Guaraldi, G., Murri, R., Orlando, G., Orlandi, E., Sterrantino, G., Borderi, M., et al. (2003). Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clinical Trials, 4, 99-106.
28. Herek, G.M., & Glunt, E.K. (1988). An epidemic of stigma: Public reactions to AIDS. American Psychologist, 43, 886.
29. Highleyman, L. (2005). Mortality trends: Toward a new definition of AIDS? Beta, 17, 18-28.
30. Hirsch, H.H., & Battegay, M. (2002). Lipodystrophy syndrome by HAART in HIV-infected patients: Manifestation, mechanisms and management. Infection, 30, 293-298.
31. Hirsch, H.H., Kaufmann, G., Sendi, P., & Battegay, M. (2004). Immune reconstitution in HIV-infected patients. Clinical Infectious Diseases, 38, 1159-1166.
32. Jones, E.E., Ferina, A., Hastorf, A.H., Markus, H., Miller, D.T., & Scott, R.A. (1984). Social Stigma: The Psychology of Marked Relationships. New York: W.H. Freeman and Company.
33. Katz, I. (1981). Stigam: A social psychological analysis. Hillsdale, New Jersey: Erlbaum.
34. Kino, T., & Chrousos, G.P. (2003). AIDS-related insulin resistance and lipodystrophy syndrome. Current Drug Targets-Immune, Endocrine & Metabolic Disorders, 3, 111-117.
35. Krueger, R.A. (1994). Focus groups: A practical guide for applied research (2nd edition). Thousand Oaks, CA.: Sage.
36. Lenert, L.A., Feddersen, M., Sturley, A., & Lee, D. (2002). Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. The American Journal of Medicine, 113, 229-232.
37. Lincoln, Y.C., & Guba, E.G. (1985). Naturalistic Inquiry. Beverly Hills: Sage.
38. Lofland, J., & Lofland, L.H. (1984). Analyzing social settings: A guide to qualitative observation and analysis. Belmont, CA.: Wadsworth.
39. Manfredi, R., Calza, L., & Chiodo, F. (2004). Another emerging event occurring during HIV infection treated with whatsoever antiretroviral therapy: Frequency and role of gynecomastia. Infections in Medicine, 12, 51-59.
40. Mayer, K.H., Hogan, J.W., Smith, D., Klein, R.S., Schuman, P., Margolick, J., et al. (2003). Clinical and immunologic progression in HIV-infected US women before and after the introduction of highly active antiretroviral therapy. Journal Acquired Immune Deficiency Syndrome, 33, 614-624.
41. Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss, P., D'arminio Monforte, A., et al. (2003). Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet, 362, 22-29.
42. Montessori, V., Press, N., Harris, M., Akagi, L., & Montaner, J.S. (2004). Adverse effects of antiretroviral therapy for HIV infection. Canadian Medical Association Journal, 170, 229-238.
43. Morgan, D.L. (1997). Focus groups as qualitative research (2nd edition). Thousand Oaks, CA: Sage.
44. Morse, J.M., & Field, P.A. (1995). Qualitative research methods for health professionals. Thousand Oaks, CA: Sage.
45. Moyle, G.J., Baldwin, C., Langroudi, B., Mandalia, S., & Gazzard, B.G. (2003). A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. Journal Acquired Immune Deficiency Syndrome, 33, 22-28.
46. Nicholas, P.K., Kirksey, K.M., Corless, I.B., & Kemppainen, J. (2005). Lipodystrophy and quality of life in HIV: Symptom management issues. Applied Nursing Research, 18, 55-58.
47. Nolan, D. (2003). Metabolic complications associated with HIV protease inhibitor therapy. Drugs, 63, 2555-2574.
48. Nolan, D., Reiss, P., & Mallal, S. (2005). Adverse effects of antiretroviral therapy for HIV infection: A review of selected topics. Expert Opinion on Drug Safety, 4, 201-218.
49. Oette, M., Juretzko, P., Kroidl, A., Sagir, A., Wettstein, M., Siegrist, J., et al. (2002). Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care and STDS, 16, 413-417.
50. Orentreich, D., & Leone, A.S. (2004). A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone. Dermatologic Surgery, 30, 548-551.
51. Palella, F.J. Jr., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV outpatient study investigators. New England Journal of Medicine, 338, 853-860.
52. Piliero, P.J., Hubbard, M., King, J., & Faragon, J.J. (2003). Use of ultrasonography-assisted liposuction for the treatment of human immunodeficiency virus-associated enlargement of the dorsocervical fat pad. Clinical Infectious Diseases, 37, 1374-1377.
53. Power, R., Tate, H.L., Mcgill, S.M., & Taylor, C. (2003). A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sexually Transmitted Infections, 79, 137-141.
54. Roberts, K.J. (2000). Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens. AIDS Patient Care and STDS, 14, 155-168.
55. Rodriguez De La Concepcion, M.L., Domingo, J.C., Domingo, P., Giralt, M., & Villarroya, F. (2004). Uncoupling protein 1 gene expression implicates brown adipocytes in highly active antiretroviral therapy-associated lipomatosis. Aids, 18, 959-960.
56. Sandelowski, M. (1995). Sample size in qualitative research. Research in Nursing and Health, 18, 179-183.
57. Sattler, F. (2003). Body habitus changes related to lipodystrophy. Clinical Infectious Diseases, 36, S84-S90.
58. Sekhar, R.V., Jahoor, F., Pownall, H.J., Ballantyne, C.M., & Balasubramanyam, A. (2004). Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy. Current Atherosclerosis Reports, 6, 173-179.
59. Sepkowitz, K.A. (2001). AIDS: The first 20 years. New England Journal of Medicine, 344, 1764-1772.
60. Strauss, A. (1981). Chronic illness. In P.C.R. Kern (Ed.), The sociology of health and illness: Critical perspectives (pp. 138-149). New York, NY: St. Martin's.
61. Strauss, A. (1990). A trajectory model for reorganizing the health care system. In Perspectives in nursing 1989-1991 (pp. 221-231). New York: National League for Nursing 44-2281.
62. Strauss, A.L., Corbin, J., Fagerhaugh, S., Glaser, B.G., Maines, D., Suczek, B., et al. (1984). Chronic illness and the quality of life (2nd edition). St. Louis: Mosby.
63. Sullivan, J.R., Rachlis, A., & Phillips, E. (2003). Buffalo-hump' dermatitis: A hat trick of antiretroviral side-effects. Contact Dermatitis, 48, 169-170.
64. Thorne, S.E. (1993). Negotiating health care: The social context of chronic illness. Newbury Park: Sage.
65. Tien, P.C., & Grunfeld, C. (2004). What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Current Opinion in Infectious Diseases, 17, 27-32.
66. Van Gaal, L.F., Mertens, I.L., & Abrams, P.J. (2003). Health risks of lipodystrophy and abdominal fat accumulation: Therapeutic possibilities with leptin and human growth hormone. Growth Hormone & IGF Research, 13(Suppl. A), S4-S9.
67. Warren, S.M., & May, J.W. Jr. (2005). Images in clinical medicine: Lipodystrophy induced by antiretroviral therapy. New England Journal of Medicine, 352, 63.
68. Wohl, D.A. (2004). Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV Infection and its therapies. Topics in HIV Medicine, 12, 89-93.